Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines
Open Access
- 14 November 2019
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (22)
Abstract
Broadly neutralizing Abs targeting the HA stem can provide broad protection against different influenza subtypes, raising the question of how best to elicit such Abs. We have previously demonstrated that vaccination with pandemic live-attenuated influenza vaccine (pLAIV) establishes immune memory for HA head-specific Abs. Here, we determine the extent to which matched versus mismatched LAIV-inactivated subunit vaccine (IIV) prime-boost vaccination elicits stem-specific memory B cells and Abs. We vaccinated African green monkeys with H5N1 pLAIV-pIIV or H5N1 pLAIV followed by seasonal IIV (sIIV) or with H5N1 pLAIV alone and measured Abs and HA-specific B cell responses. While we observed an increase in stem-specific memory B cells, head-specific memory B cell responses were substantially higher than stem-specific responses and were dominant even following boost with mismatched IIV. Neutralizing Abs against heterologous influenza viruses were undetectable. Head-specific B cells from draining lymph nodes exhibited germinal center markers, while stem-specific B cells found in the spleen and peripheral blood did not. Thus, although mismatched prime-boost generated a pool of stem-specific memory B cells, head-specific B cells and serum Abs substantially dominated the immune response. These findings have implications for including full-length native HA in prime-boost strategies intended to induce stem-specific Abs for universal influenza vaccination.Keywords
Funding Information
- NIAID, NIH (N/A)
This publication has 45 references indexed in Scilit:
- Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cellsProceedings of the National Academy of Sciences, 2012
- Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti-Influenza A AntibodiesClinical Infectious Diseases, 2011
- An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adultsVaccine, 2011
- Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infectionJournal of Experimental Medicine, 2011
- A Live Attenuated H7N7 Candidate Vaccine Virus Induces Neutralizing Antibody That Confers Protection from Challenge in Mice, Ferrets, and MonkeysJournal of Virology, 2010
- Evaluation of Replication and Cross-Reactive Antibody Responses of H2 Subtype Influenza Viruses in Mice and FerretsJournal of Virology, 2010
- A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adultsVaccine, 2009
- A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy AdultsThe Journal of Infectious Diseases, 2009
- Evaluation of Live Attenuated Influenza A Virus H6 Vaccines in Mice and FerretsJournal of Virology, 2009
- A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferretsVirology, 2008